Revolution Medicines - Biotech Company Targeted by Merck & Co!
Reading Time: 2 minutes
Business Driver: Revolution Medicines (RVMD) specializes in developing new therapies for the treatment of cancer and tumor cells. At the center are the so-called RAS(ON) inhibitors and RAS co-inhibitors targeting hard-to-treat tumors. Currently, they have three products in advanced phases of clinical testing: Daraxonrasib (RMC-6236), Zoldonrasib (RMC-9805), and Elironrasib (RMC-6291). Daraxonrasib is considered one of the most promising products in Revolution Medicines' portfolio. The FDA has already granted it Breakthrough Status for the indication...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
